Presented by Jessica Palmer at the Society for Birth Defects and Research Meeting; June, 2022
There have been increased efforts in the pharmaceutical and chemical industries to incorporate new approach methods (NAMs) in vitro,, ex vivo, or in silico) earlier in the product development pipeline prior to in vivo testing.
Presented by Jessica Palmer at the Society for Toxicology Meeting; March, 2022
There have been increased efforts in the pharmaceutical and chemical industries to incorporate new approach methods (NAMs) (in vitro, ex vivo, or in silico) earlier in the product development pipeline prior to in vivo testing.
Presented by Jessica Palmer at the 11th World Congress on Alternatives and Animal Use in the Life Sciences; August, 2021
Implementing screening assays that identify functional and structural cardiotoxicity earlier in the drug development pipeline has the potential to improve safety and the cost and time required to bring new drugs to market.
Presented by Jessica Palmer at the 11th World Congress on Alternatives and Animal Use in the Life Sciences; August, 2021
Assessing the accuracy, reproducibility, and applicability domain of new approach methods (NAMs) is necessary step for establishing confidence in these methods and enabling their use in a regulatory setting.
Presented by Jessica Palmer at the Society for Toxicology Meeting; March, 2021
Tyrosine kinase inhibitors (TKI) have greatly improved the treatment and prognosis for a wide range of cancers. Unfortunately, numerous TKIs produce cardiotoxic effects, which were not well predicted during preclinical studies.
Stemina’s neurological disorders business unit has developed a test to aid in the earlier diagnosis of autism spectrum disorder.